このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Placebo Effect on Cycling Performance: Laboratory Crossover Study

2026年9月15日 更新者：Poznan University of Physical Education

The Impact of Expectations on Physical Performance and Psychophysiological Potential: a Randomized, Double-blind, Placebo-controlled Crossover Study on the Placebo Effect in the Context of Caffeine Supplementation

This study aims to determine the impact of the placebo (PLA) effect on physical and cognitive performance in a controlled laboratory setting. The study investigates how expectations and beliefs about substance intake (caffeine vs. placebo) interact with actual consumption to influence performance and physiological stress markers. Healthy adults (n = 80) will participate in four testing sessions using a randomized, double-blind, placebo-controlled crossover design. Physiological stress markers (cortisol and alpha-amylase), heart rate, and performance metrics will be monitored during a standardized cycling exercise protocol. This phase provides the dense mechanistic data required to refine a mathematical model of the placebo effect, offering insights into how individual personality traits and cognitive anchoring influence psychophysiological potential.

調査の概要

状態

まだ募集していません

条件

介入・治療

詳細な説明

This study employs a randomized, double-blind, placebo-controlled crossover design to conduct a multifactorial analysis of psychophysiological and biomechanical dynamics. Participants (n = 80, aged 20-35 years) will complete four experimental sessions separated by 7-day washout periods, involving caffeine (6 mg/kg) or placebo administration. The laboratory protocol (160 minutes) integrates multiple modalities: (1) cognitive testing (Reaction Time Test and Flanker Test), (2) postural control assessment using the BTrackS Balance Plate, and (3) a standardized cycle ergometer exercise protocol consisting of 15 minutes at the anaerobic threshold followed by a 5-minute self-paced maximal effort trial. Belief manipulation (immediate vs. retrospective reporting) and cognitive anchoring (feedback conditions) are implemented to isolate expectancy-driven effects. Continuous metabolic and cardiorespiratory data collected using the Cosmed K5 system will be synchronized with blood biomarkers (lactate, glucose, caffeine, and paraxanthine) and salivary biomarkers (cortisol, testosterone, and alpha-amylase). Advanced statistical methods, including Functional Data Analysis (FDA) and machine learning, will be used to integrate physiological trajectories with behavioral predictors.

研究の種類

介入

入学 (推定)

80

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

  • ポーランド
    • Wielkopolska
      • Poznan、Wielkopolska、ポーランド
        • Poznań University of Physical Education
        • コンタクト：

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人

健康ボランティアの受け入れ

はい

説明

Inclusion Criteria:

  • Age between 20 and 35 years,
  • Healthy adults,
  • Regular physical activity, but not professional athletes,
  • Normal or corrected-to-normal vision,
  • Habitual caffeine consumption.

Exclusion Criteria:

  • History of neurological, psychiatric, cardiovascular, or metabolic disorders,
  • Current use of medication or supplements affecting the central nervous system,
  • Musculoskeletal injuries that would impair physical performance,
  • No habitual caffeine consumption or severe negative side effects of caffeine,
  • Diagnosed sleep disorders or chronic fatigue,
  • Diagnosed major depressive disorder or other severe psychiatric conditions,
  • Presence of any menstrual disorders,
  • Inability to attend all experimental study visits.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

  • 主な目的：基礎科学
  • 割り当て：ランダム化
  • 介入モデル：クロスオーバー割り当て
  • マスキング：4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的：Sequence AABB
Participants follow the sequence: Caffeine, Caffeine, Placebo, Placebo, with a 7-day washout period between sessions.
薬：Caffeine (6mg/kg)
Anhydrous caffeine administered in an encapsulated form at a dosage of 6 mg per kilogram of body mass, 60 minutes before the exercise protocol.
他の：Placebo (Starch capsule)
Corn starch administered in an identical encapsulated form as the active caffeine, 60 minutes prior to the laboratory exercise protocol.
実験的：Sequence BBAA
Participants follow the sequence: Placebo, Placebo, Caffeine, Caffeine, with a 7-day washout period between sessions.
薬：Caffeine (6mg/kg)
Anhydrous caffeine administered in an encapsulated form at a dosage of 6 mg per kilogram of body mass, 60 minutes before the exercise protocol.
他の：Placebo (Starch capsule)
Corn starch administered in an identical encapsulated form as the active caffeine, 60 minutes prior to the laboratory exercise protocol.
実験的：Sequence ABAB
Participants follow the sequence: Caffeine, Placebo, Caffeine, Placebo, with a 7-day washout period between sessions.
薬：Caffeine (6mg/kg)
Anhydrous caffeine administered in an encapsulated form at a dosage of 6 mg per kilogram of body mass, 60 minutes before the exercise protocol.
他の：Placebo (Starch capsule)
Corn starch administered in an identical encapsulated form as the active caffeine, 60 minutes prior to the laboratory exercise protocol.
実験的：Sequence BABA
Participants follow the sequence: Placebo, Caffeine, Placebo, Caffeine, with a 7-day washout period between sessions.
薬：Caffeine (6mg/kg)
Anhydrous caffeine administered in an encapsulated form at a dosage of 6 mg per kilogram of body mass, 60 minutes before the exercise protocol.
他の：Placebo (Starch capsule)
Corn starch administered in an identical encapsulated form as the active caffeine, 60 minutes prior to the laboratory exercise protocol.

この研究は何を測定していますか？

主要な結果の測定

結果測定
メジャーの説明
時間枠
Physical Work Capacity (total work in J)
時間枠：Measured during each laboratory exercise protocol (approximately 85-120 minutes).
Total physical work performed, expressed in Joules (J), during the standardized laboratory exercise protocol, including both the Anaerobic Threshold phase and the Self-paced Maximal Time-trial.
Measured during each laboratory exercise protocol (approximately 85-120 minutes).
Postural Control (mm)
時間枠：Measured continuously during the exercise protocol and at T1 (minute 2), T2 (minute 55), and T3 (minute 125).
Center of Pressure excursions measured using the BTrackS Balance Plate and expressed in millimeters (mm).
Measured continuously during the exercise protocol and at T1 (minute 2), T2 (minute 55), and T3 (minute 125).
Explosive power variables (mm)
時間枠：Continuous recording throughout the exercise protocol and discrete assessments at T1 (2 minute of protocol), T2 (55 minute of protocol), and T3 (125 minute of protocol).
Explosive lower-limb power expressed in millimeters (mm) - Countermovement Jump - height.
Continuous recording throughout the exercise protocol and discrete assessments at T1 (2 minute of protocol), T2 (55 minute of protocol), and T3 (125 minute of protocol).
Psychomotor Vigilance Test Reaction Time (ms)
時間枠：Measured at T1 (pre-ingestion, minute 2 of the protocol), T2 (post-ingestion/pre-exercise, minute 55 of the protocol), and T3 (post-exercise, minute 125 of the protocol).
Reaction time during the Psychomotor Vigilance Test expressed in milliseconds (ms).
Measured at T1 (pre-ingestion, minute 2 of the protocol), T2 (post-ingestion/pre-exercise, minute 55 of the protocol), and T3 (post-exercise, minute 125 of the protocol).
Flanker Test Reaction Time (ms)
時間枠：Measured at T1 (pre-ingestion, minute 2 of the protocol), T2 (post-ingestion/pre-exercise, minute 55 of the protocol), and T3 (post-exercise, minute 125 of the protocol).
Reaction time during the Flanker Test expressed in milliseconds (ms).
Measured at T1 (pre-ingestion, minute 2 of the protocol), T2 (post-ingestion/pre-exercise, minute 55 of the protocol), and T3 (post-exercise, minute 125 of the protocol).

二次結果の測定

結果測定
メジャーの説明
時間枠
Exercise Heart Rate (bpm)
時間枠：Measured continuously during each laboratory exercise protocol (approximately 85-120 minutes).
Heart rate expressed in beats per minute (bpm) recorded continuously throughout the standardized laboratory exercise protocol.
Measured continuously during each laboratory exercise protocol (approximately 85-120 minutes).
Exercise Heart Rate Variability (ms)
時間枠：Measured continuously during each laboratory exercise protocol (approximately 85-120 minutes).
Heart rate variability expressed in milliseconds (ms) and recorded continuously throughout the standardized laboratory exercise protocol to assess autonomic regulation.
Measured continuously during each laboratory exercise protocol (approximately 85-120 minutes).
Simple Reaction Time (ms)
時間枠：Measured at T1 (pre-ingestion, minute 2 of the protocol), T2 (post-ingestion/pre-exercise, minute 55 of the protocol), and T3 (post-exercise, minute 125 of the protocol).
Reaction time during the Simple Reaction Time test expressed in milliseconds (ms).
Measured at T1 (pre-ingestion, minute 2 of the protocol), T2 (post-ingestion/pre-exercise, minute 55 of the protocol), and T3 (post-exercise, minute 125 of the protocol).
Heart Rate Recovery (bpm)
時間枠：Measured continuously during the first 5 minutes immediately following exercise cessation.
Heart rate recorded during the post-exercise recovery period, expressed in beats per minute (bpm).
Measured continuously during the first 5 minutes immediately following exercise cessation.
Rating of Perceived Exertion (Borg Scale, points)
時間枠：Before and immediately after warm-up, immediately after the Anaerobic Threshold phase, immediately after the Self-paced Maximal Time-trial, and immediately after cooldown during each laboratory study visit.
Perceived exertion will be assessed using the Borg Rating of Perceived Exertion Scale and reported in points (6-20).
Before and immediately after warm-up, immediately after the Anaerobic Threshold phase, immediately after the Self-paced Maximal Time-trial, and immediately after cooldown during each laboratory study visit.
Personality Traits (NEO-FFI, points)
時間枠：Measured at baseline (first study visit).
Personality traits will be assessed using the NEO Five-Factor Inventory (NEO-FFI). The questionnaire provides scores for five personality domains: Neuroticism, Extraversion, Openness to Experience, Agreeableness, and Conscientiousness. Results will be reported as domain scores in points.
Measured at baseline (first study visit).
Mood State (POMS/BRUMS) (points)
時間枠：Measured during each laboratory study visit.
Mood state assessed using the Profile of Mood States (POMS/BRUMS), expressed in points.
Measured during each laboratory study visit.
Caffeine Expectancy (Caff-EQ-Brief) (points)
時間枠：Measured 30 minutes post-ingestion.
Caffeine expectancy assessed using the Caffeine Expectancy Questionnaire-Brief (Caff-EQ-Brief), expressed in points.
Measured 30 minutes post-ingestion.
Urine pH
時間枠：Measured once prior to the start of each laboratory study visit.
Urine pH measured using a urine strip analyzer.
Measured once prior to the start of each laboratory study visit.
White blood cells count and differential (count/L)
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
White blood cells count and differential (%)
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Hematological indices (red blood cells, RBC) (count/L)
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Hematological indices (hemoglobin concentration, HGB) (mmol/L)
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Hematological indices (hematocrit, HCT) (L/L)
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Hematological indices (mean corpuscular volume, MCV; mean platelet volume, MPV) (fL)
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Hematological indices (mean corpuscular hemoglobin mass, MCH) (fmol)
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Hematological indices (mean corpuscular hemoglobin concentration, MCHC) (mmol/L)
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Hematological indices (platelet count, PLT) (count/L)
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Hematological indices (platelet hematocrit, PCT) (cL/L)
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Hematological indices (platelet distribution width, PDW; platelet large cell ratio, PLCR; red blood cells distribution width - coefficient of variation, RDW-C) (%)
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Hematological indices (red blood cells distribution width - standard deviation, RDW-S) (fL)
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Urea Concentration (mmol/L)
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Urea concentration measured from fingertip capillary blood and expressed in mmol/L.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Glucose Concentration (mg/dL)
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Glucose concentration measured from fingertip capillary blood and expressed in mg/dL.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Creatinine concentration (μmol/L)
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Creatinine concentration measured from fingertip capillary blood and expressed in µmol/L.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Muscle damage markers (activity of alanine aminotransferase, aspartate aminotransferase, creatine kinase, lactate dehydrogenase) (U/L)
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Assessment of the muscle damage markers (activity of alanine aminotransferase, aspartate aminotransferase, creatine kinase, lactate dehydrogenase) (U/L) will be performed from fingertip capillary blood.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Lactate concentration (mmol/L)
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Blood lactate concentration measured from fingertip capillary blood and expressed in mmol/L.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Electrolites' concentration (Ca, Na, K, Cl) (mmol/L)
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Assessment of electrolites' concentration (Ca, Na, K, Cl) (mmol/L) will be performed from fingertip capillary blood.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Blood pH
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Assessment of gasometry markers (blood pH) will be performed from fingertip capillary blood.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Partial Pressure of Carbon Dioxide and Oxygen (pCO2, pO2) (mmHg)
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Assessment of gasometry markers (pCO2, pO2) (mmHg) will be performed from fingertip capillary blood.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
CAF and PAX concentrations (µmol/L)
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Assessment of caffeine and paraxanthine concentrations (µmol/L) will be performed from fingertip capillary blood.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
Static weight distribution (mm)
時間枠：Measured at the start of each study visit.
Static weight distribution expressed in millimeters of Center of Pressure symmetry.
Measured at the start of each study visit.
Analysis of body composition (fat-free mass, fat mass) (kg)
時間枠：Measured at the start of each study visit.
Assessment of body composition (fat-free mass, fat mass) (kg) will be carried out at the start of each study visit.
Measured at the start of each study visit.
Analysis of body composition (total body water) (L)
時間枠：Measured at the start of each study visit.
Assessment of body composition (total body water) (L) will be carried out at the start of each study visit.
Measured at the start of each study visit.
Analysis of body composition (total body water) (%)
時間枠：Measured at the start of each study visit.
Assessment of body composition (total body water) (%) will be carried out at the start of each study visit.
Measured at the start of each study visit.
Autonomic Response during Cognitive Performance (bpm)
時間枠：Measured at three time points: T1 (pre-ingestion; 2 minute of protocol), T2 (post-ingestion/pre-exercise; 55 minute of protocol), and T3 (post-exercise; 125 minute of protocol).
Heart rate and heart rate variability recording during cognitive testing blocks, expressed in beats per minute (bpm).
Measured at three time points: T1 (pre-ingestion; 2 minute of protocol), T2 (post-ingestion/pre-exercise; 55 minute of protocol), and T3 (post-exercise; 125 minute of protocol).
Anthropometric Indices (kg)
時間枠：Measured at the start of each study visit.
Body mass in kilograms will be measured at the start of each study visit.
Measured at the start of each study visit.
Anthropometric Indices (metres)
時間枠：Measured at the start of each study visit.
Height in metres will be measured at the start of each study visit.
Measured at the start of each study visit.
Explosive power variables (ms)
時間枠：Continuous recording throughout the exercise protocol and discrete assessments at T1 (2 minute of protocol), T2 (55 minute of protocol), and T3 (125 minute of protocol).
Explosive lower-limb power variables expressed in milliseconds (ms) - Countermovement Jump - contact time and flight time.
Continuous recording throughout the exercise protocol and discrete assessments at T1 (2 minute of protocol), T2 (55 minute of protocol), and T3 (125 minute of protocol).
Explosive power variables (W)
時間枠：Continuous recording throughout the exercise protocol and discrete assessments at T1 (2 minute of protocol), T2 (55 minute of protocol), and T3 (125 minute of protocol).
Explosive lower-limb power expressed in Watts (W) - Countermovement Jump - power.
Continuous recording throughout the exercise protocol and discrete assessments at T1 (2 minute of protocol), T2 (55 minute of protocol), and T3 (125 minute of protocol).
Hydration Status (g/mL)
時間枠：Once prior to the start of each laboratory study visit.
Assessment of urine specific gravity (g/mL) using a urine strip analyzer.
Once prior to the start of each laboratory study visit.
Flanker Test Accuracy (%)
時間枠：Measured at T1 (pre-ingestion, minute 2 of the protocol), T2 (post-ingestion/pre-exercise, minute 55 of the protocol), and T3 (post-exercise, minute 125 of the protocol).
Accuracy during the Flanker Test expressed as the percentage of correct responses.
Measured at T1 (pre-ingestion, minute 2 of the protocol), T2 (post-ingestion/pre-exercise, minute 55 of the protocol), and T3 (post-exercise, minute 125 of the protocol).
Heart Rate Variability Recovery (ms)
時間枠：Measured continuously during the first 5 minutes immediately following exercise cessation.
Heart rate variability expressed in milliseconds (ms) during the post-exercise recovery period.
Measured continuously during the first 5 minutes immediately following exercise cessation.
Caffeine Expectancy Questionnaire Score (points)
時間枠：Measured 30 minutes post-ingestion.
Caffeine expectancy assessed using the Caffeine Expectancy Questionnaire and expressed in points.
Measured 30 minutes post-ingestion.
Suggestibility (SSS) (points)
時間枠：Measured during the last study visit.
General suggestibility assessed using the Short Suggestibility Scale (SSS), expressed in points.
Measured during the last study visit.
Intrinsic Motivation (IMI) (points)
時間枠：Measured after each test block during every laboratory study visit.
Task-specific intrinsic motivation assessed using the Intrinsic Motivation Inventory (IMI), expressed in points.
Measured after each test block during every laboratory study visit.
Sport Motivation (SMS) (points)
時間枠：Measured during the first study visit.
Sport motivation assessed using the Sport Motivation Scale (SMS), expressed in points.
Measured during the first study visit.
Sleep Quality (LSEQ) (points)
時間枠：Measured once during each laboratory study visit.
Subjective sleep quality assessed using the Leeds Sleep Evaluation Questionnaire (LSEQ), expressed in points.
Measured once during each laboratory study visit.
Salivary Cortisol Concentration (nmol/L)
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before warm-up (60 minutes post-ingestion), 3 minutes post-exercise, and 10 minutes post-exercise.
Salivary cortisol concentration expressed in nmol/L.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before warm-up (60 minutes post-ingestion), 3 minutes post-exercise, and 10 minutes post-exercise.
Salivary Testosterone Concentration (pmol/L)
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before warm-up (60 minutes post-ingestion), 3 minutes post-exercise, and 10 minutes post-exercise.
Salivary testosterone concentration expressed in pmol/L.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before warm-up (60 minutes post-ingestion), 3 minutes post-exercise, and 10 minutes post-exercise.
Salivary Alpha-amylase Activity (U/L)
時間枠：Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before warm-up (60 minutes post-ingestion), 3 minutes post-exercise, and 10 minutes post-exercise.
Salivary alpha-amylase activity expressed in U/L.
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before warm-up (60 minutes post-ingestion), 3 minutes post-exercise, and 10 minutes post-exercise.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

Poznan University of Physical Education

捜査官

  • 主任研究者：Jakub Malik, PhD、Poznan University of Physical Education, Department of Sports Psychology

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2027年1月1日

一次修了 (推定)

2028年3月31日

研究の完了 (推定)

2029年3月31日

試験登録日

最初に提出

2026年7月21日

QC基準を満たした最初の提出物

2026年7月31日

最初の投稿 (実際)

2026年8月5日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月18日

QC基準を満たした最後の更新が送信されました

2026年9月15日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

キーワード

追加の関連 MeSH 用語

その他の研究ID番号

  • 152-2-26
  • 2025/57/N/NZ4/04470 (その他の助成金/資金番号：National Science Centre)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The study protocol will be published as an open-access article. Upon completion of the study, de-identified individual participant data (IPD) and relevant analytic code will be deposited in an open-access repository such as Zenodo or OSF, following the FAIR principles.

IPD 共有時間枠

The study protocol will be available upon its publication. The IPD and analytic code will be available starting from the date of the primary study results publication and will remain accessible for at least 5 years.

IPD 共有アクセス基準

The study protocol will be published as an open-access article. Upon completion of the study, de-identified individual participant data (IPD) and relevant analytic code will be deposited in an open-access repository such as Zenodo or OSF, in accordance with FAIR principles.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する